Asia/Oceania
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Genetron Health Partners with Guizhou Local Government for Liver Cancer Early Screening Project
The firm will provide testing using its HCCscreen assay and help develop follow-up procedures as part of an effort to advance cancer early detection in rural areas of China.
Hutchmed, AstraZeneca Begin Orpathys Study in Gastric Cancer Patients
The Phase II trial is exploring the activity of the drug in MET-amplified, previously treated, advanced gastric cancer patients.
Micronoma, University of New South Wales to Develop Liver Cancer Dx Using $4M Grant
University researchers will use the firm's platform to analyze microbiome biomarkers to develop a noninvasive early detection method for hepatocellular carcinoma.
GenesisCare Takes Minority Stake in Precision Medicine Firm PreludeDx
Earlier this year, the companies signed a deal to expand access to PreludeDx's DCISionRT precision medicine breast cancer test in Australia and the US.